RICARDO
RUIZ VILLAVERDE
Hospital Universitario Reina Sofia
Córdoba, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (32)
2024
-
Acne keloidalis nuchae: An international multicentric review of 79 patients
Journal of the European Academy of Dermatology and Venereology
-
Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up
Dermatitis, Vol. 35, pp. S55-S61
-
Real-World Safety and Efficacy Profile of Baricitinib in Patients With Atopic Dermatitis: a Multicenter Retrospective Trial From Four Spanish Hospitals in Andalusia
Actas Dermo-Sifiliograficas
2023
-
Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice
Journal of Clinical Medicine, Vol. 12, Núm. 17
-
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997
-
Upadacitinib for moderate to severe atopic dermatitis
Immunotherapy, Vol. 15, Núm. 11, pp. 799-808
-
Updated Review on Treatment of Atopic Dermatitis
Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167
-
[Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501
2022
-
Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)
Life
-
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study
F1000Research, Vol. 11
-
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis
Dermatologic Therapy, Vol. 35, Núm. 10
-
Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab
Dermatologic Therapy, Vol. 35, Núm. 11
-
Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review
Life, Vol. 12, Núm. 8
-
Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
Life, Vol. 12, Núm. 11
-
Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series
International Journal of Dermatology, Vol. 61, Núm. 8, pp. 1029-1033
-
Tildrakizumab: short-term efficacy and safety in real clinical practice
International Journal of Dermatology
-
Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning
International journal of environmental research and public health, Vol. 19, Núm. 17
2021
-
Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study
British Journal of Dermatology
-
Risankizumab: A pilot study of short-term effectiveness and safety in real clinical practice
Dermatologic Therapy
-
Secukinumab: Drug Survival in Clinical Practice Settings
Actas Dermo-Sifiliograficas, Vol. 112, Núm. 4, pp. 361-364